EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants

Jingjing Wang, Jinjie He, Jufang Wu, Jing Zhang, Ying Ma, Xiaoqing Ren, Hua Wei, Chunye Zhang, Hua Zhu, Susan R Raber, Shuangchen Cong

Clinical Pharmacology in Drug Development · 2026-02 · 15 (2)

DOI: 10.1002/cpdd.70040 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 19.02.2026. Verfasst von Jingjing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Biomedical Advanced Research and Development Authority, Pfizer Inc. Aztreonam-avibactam, Pfizer and AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs). Aztreonam–avibactam may also address other problematic β‐lactamases, such as extended‐spectrum β‐lactamases and serine carbapenemases, which may be co‐expressed with MBLs and contribute to a multidrug‐resistant phenotype. Based on completion of two Phase 3 trials, aztreonam–avibactam was approved in Europe (2024), the United States and China (2025). This Phase 1 open‐label study assessed the pharmacokinetics, safety, and tolerability of aztreonam–avibactam in healthy Chinese participants after single‐ and multiple‐dose administration (doses equivalent to those evaluated in Phase 3 aztreonam–avibactam trials), with a fixed 3:1 ratio. Pharmacokinetics, safety, and tolerability characteristics of aztreonam and avibactam were consistent with previous knowledge, with no clinically significant differences in exposures between Chinese and non‐Chinese participants. Based on population pharmacokinetic modeling which incorporated data from the aztreonam–avibactam Phase 1–3 trials, predicted aztreonam and avibactam exposures at steady state for Phase 3 participants in China and non‐China (rest‐of‐world) regions were numerically similar. These findings indicate that aztreonam–avibactam is well tolerated in healthy Chinese adults and support the use of the approved dose regimen by EMA for Chinese patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase InhibitorsEast Asian PeopleAdultFemaleHumansMaleMiddle AgedYoung AdultChinaDrug Administration ScheduleDrug CombinationsHealthy Volunteers

Stichwörter der Autor:innen

antimicrobial resistanceclinical trialsmetallo β‐lactamasemultidrug‐resistant pathogenspharmacokineticsβ‐lactam/β‐lactamase inhibitor

Substanzen

Anti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonamaztreonam, avibactam drug combinationbeta-Lactamase InhibitorsDrug Combinations

Autor:innen und Institutionen

  • Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Pfizer (China) Research and Development Co., Ltd, Shanghai, China.
  • Pfizer Pharmaceutical Ltd., Development China, Beijing, China.
  • Pfizer Research & Development, Pfizer Inc., San Diego, CA, USA.

Förderung

  • the Biomedical Advanced Research and Development Authority
  • Pfizer Inc. Aztreonam-avibactam
  • Pfizer and AbbVie
  • Innovative Medicines Initiative COMBACTE-CARE group

Zitieren

APA

Wang, J., He, J., Wu, J., Zhang, J., Ma, Y., Ren, X., Wei, H., Zhang, C., Zhu, H., Raber, S. R., & Cong, S. (2026). Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants. Clinical Pharmacology in Drug Development, 15(2). https://doi.org/10.1002/cpdd.70040

Vancouver

Wang J, He J, Wu J, Zhang J, Ma Y, Ren X, et al. Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants. Clinical Pharmacology in Drug Development. 2026;15(2). doi:10.1002/cpdd.70040

BibTeX
@article{Wang2026,
  author = {Wang, Jingjing and He, Jinjie and Wu, Jufang and Zhang, Jing and Ma, Ying and Ren, Xiaoqing and Wei, Hua and Zhang, Chunye and Zhu, Hua and Raber, Susan R and Cong, Shuangchen},
  title = {Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {2},
  doi = {10.1002/cpdd.70040}
}
Kostenlos starten →